Phase 2 Breast Cancer Trial, Recruiting NCT07104266 Sponsor: Université de Sherbrooke Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07104266
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman (female)
  • You are 18 years old or older
  • Your breast cancer is at an early stage
  • Your cancer has been confirmed as "triple-negative breast cancer" (TNBC) by a lab test
  • Your cancer has not spread beyond nearby lymph nodes (ranging from no lymph node involvement to some regional lymph node involvement)
  • There is no sign that your cancer has spread to other parts of your body
  • You have already had breast-conserving surgery (a surgery that removes the tumor but keeps most of the breast) with clean edges around the removed tissue

Who may not be able to join:

  • You have had a stomach ulcer in the last six months
  • You have had significant kidney problems in the last six months (confirm with trial site)
  • You have had significant liver problems in the last six months, including abnormal liver test results or advanced liver scarring (confirm with trial site)
  • You have had heart failure with reduced pumping ability in the last six months (confirm with trial site)
  • You are currently taking anti-inflammatory painkillers (such as ibuprofen or naproxen) for another condition, or were taking them before starting radiation treatment
  • You have had a bad reaction or allergy to a medication called celecoxib in the past
  • You have a history of allergic reactions to a group of medications called sulfonamides (confirm with trial site)
  • You have a history of asthma attacks, hives, or allergic reactions after taking aspirin or other anti-inflammatory painkillers
  • You have a condition causing ongoing inflammation of the bowel (such as Crohn's disease or ulcerative colitis)
  • You have been diagnosed with high potassium levels in your blood (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Université de Sherbrooke
Registry
ClinicalTrials.gov
Start date
4 August 2025
Est. completion
4 August 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Number of participants needed to assess the reduction in recurrence rate by administering celecoxid during radiotherapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov